Currently, carcinoembryonic antigen 19–9 (CA19-9) is the most commonly used tumor-associated antigen for the serological diagnosis and prognosis evaluation of pancreatic cancer [3], but its specificity in distinguishing pancreatic cancer from biliary diseases is not satisfactory. This evidence concerns the gene CEACAM5 and pancreatic neoplasm.